91419-49-7

Basic information

• Product Name: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE
• Synonyms: 3-CARBAMOYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-N-BOC-PIPERIDINE-3-CARBOXAMIDE;1-N-Boc-3-piperidinecarboxamide;1-TERT-BUTOXYCARBONYL-3-METHYLAMINOPIPERIDINE;1-Boc-piperidine-3-carboxamide;1-Piperidinecarboxylic acid, 3-(aminocarbonyl)-, 1,1-dimethylethyl ester;1-N-BOC-3-CARBAMOYLPIPERIDINE;tert-butyl 3-(aminocarbonyl)piperidine-1-carboxylate
• CAS NO: 91419-49-7
• Molecular Formula: C₁₁H₂₀N₂O₃
• Molecular Weight: 228.29
• Mol File: 91419-49-7.mol

Chemical Properties

• Melting Point: 174.0 to 178.0 °C
• Boiling Point: 384.4 °C at 760 mmHg
• Flash Point: 186.3 °C
• Appearance: /
• Density: 1.123 g/cm³
• Vapor Pressure: 4.1E-06mmHg at 25°C
• Refractive Index: 1.498
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 16.41±0.20(Predicted)
• CAS DataBase Reference: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE(91419-49-7)
• EPA Substance Registry System: 1-N-BOC-PIPERIDINE-3-CARBOXAMIDE(91419-49-7)

Safety Data

• Statements: 22
• Safety Statements: 37
• Hazardous Substances Data: 91419-49-7(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Synthesis Reference(s)

Synthetic Communications, 20, p. 1203, 1990 DOI: 10.1080/00397919008052828

InChI:InChI=1/C11H20N2O3/c1-11(2,3)16-10(15)13-6-4-5-8(7-13)9(12)14/h8H,4-7H2,1-3H3,(H2,12,14)

Upstream product

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 4138-26-5 nipecotamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 498-95-3 nipecotic acid 

Downstream Products

• 91419-53-3 (+/-)-2-N-tert-butoxycabonylpiperidine-3-carbonitrile 
• 274682-80-3 3-thiocarbamoylpiperidine-1-carboxylic acid tert-butyl ester 
• 479080-28-9 tert-butyl 3-[amino(hydroxyimino)methyl]piperidine-1-carboxylate 
• 940868-22-4 tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)piperidine-1-carboxylate 
• 162167-97-7 tert-butyl 3-(aminomethyl)piperidine-1-carboxylate 
• 91419-64-6 5-<1-(tert-butoxycarbonyl)-3-piperidyl>-1H-tetrazole 
• 1271802-37-9 1-(2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)thiazol-4-yl)-3-phenylurea 
• 1192248-02-4 tert-Butyl 3-[4-(ethoxycarbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate 
• 1271808-87-7 C₂₀H₂₆N₄O₃S 
• 1271802-74-4 1-(2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)thiazol-5-yl)-3-phenylurea 
• 1271809-12-1 C₂₀H₂₆N₄O₃S 
• 1271809-14-3 C₁₅H₁₈N₄OS 
• 1258639-71-2 C₁₁H₂₁N₃O₂*ClH 

Relevant articles and documents

General Ser/Thr Kinases Pharmacophore Approach for Selective Kinase Inhibitors Search as Exemplified by Design of Potent and Selective Aurora A Inhibitors

A general pharmachophore model for various types of Ser/Thr kinases was developed. Search for the molecules fitting to this pharmacophore among ASINEX proprietary library revealed a number of compounds, which were tested and appeared to possess some activity against several Ser/Thr kinases such as Aurora A, Aurora B and Haspin. The possibility of performing the fine-tuning of the general Ser/Thr pharmacophore to desired types of kinase to get active and selective inhibitors was exemplified by Aurora A kinase. As a result, several hits in 3–5?nm range of activity against Aurora A kinase with rather good selectivity and ADME properties were obtained.

MK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Carbazole inhibitors of histamine receptors for the treatment of disease

The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors

The present invention relates to new compounds which are Oxadiazole derivatives of formula (I) wherein B, P, Q, W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by mGluR5 receptors.(I).

Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers

A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity.

NEW COMPOUNDS

The present invention relates to new compounds of formula (I) wherein Y1 and Y2 selected from the group consisting of hydrogen, halogen atom; C1-4 alkyl, C1-4alkoxy, cyano and trifluoromethyl group, Q is -CH- gr

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.

PHENYL-3-{ (3- (1H- PYRROL- 2 -YL) - [1 , 2 , 4] 0XADIAZ0L-5-YL] PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ("mGluR5") which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluKi is involved. W represents (C4-C7)cycloalkyl, (C3-C7)heterocycloalkyl , (C3-C7)heterocycloalkyl-(C1-C3)alkyl or (C3-C7)heterocycloalkenyl ring; represents a (C5-C7)heteroeycloalkyl, (C5-C7)heterocycloalkeiiyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR8C(=O)-, -NR8C(=O)-O-, -NR8C(=O)-NR9, NR8S(=O)2-, -C(=O)NR8-, -O-C(=O)NR8-, -S-, -S(=O)-, -S(=O)2-, -S(C=O)2NR8-, -C(=0)-0-, -0-C(=0)-, -C(=NR8)NR9-, C(C=NOR8)NR9- , -NR8C(=NOR9)-, =N-0-, -0-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.

SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE

The invention relates to novel compounds, which are substituted chiral or achiral derivatives of 3- or 4- aminomethylpiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula (I) and especially their use as inhibitors of beta-secretases for the treatment of Alzheimer’s disease.